NervGen Pharma Corp. (NGEN), Monday announced the appointment of Adam Rogers as President and Chief Executive Officer of the company, effective immediately.
In July 2025, Rogers was appointed as Chairman and Interim CEO of the company as part of a leadership transition supporting NervGen's next stage of growth.
"My role as CEO represents a mission-driven commitment to execution and to the individuals, families, and communities who are counting on us to achieve meaningful progress," said Rogers.
In the pre-market hours, NervGen's stock is trading at $3.82, down 1.55 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.